	US 11,833,216 B2
	Anti-EDB antibodies and antibody-drug conjugates
Andrea Therese Hooper, Port Chester, NY (US); Kimberly Ann Marquette, Somerville, MA (US); Chakrapani Subramanyam, South Glastonbury, CT (US); Hans-Peter Gerber, San Carlos, CA (US); and Chad Michael May, Belmont, CA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Feb. 9, 2023, as Appl. No. 18/166,774.
Application 18/166,774 is a continuation of application No. 16/342,275, previously published as PCT/IB2017/056093, filed on Oct. 3, 2017.
Claims priority of provisional application 62/409,081, filed on Oct. 17, 2016.
Prior Publication US 2023/0241235 A1, Aug. 3, 2023
Int. Cl. A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); A61K 38/08 (2019.01)

CPC A61K 47/6803 (2017.08) [A61K 47/6843 (2017.08); A61P 35/00 (2018.01); C07K 16/18 (2013.01); A61K 38/08 (2013.01); A61K 47/6811 (2017.08); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

25 Claims

1. An antibody-drug conjugate comprising:

(a) an antibody, or antigen binding fragment thereof, that binds to extra domain B of fibronectin and that comprises:

a heavy chain, the heavy chain comprising a constant region and a variable region, wherein the heavy chain variable region comprises SEQ ID NO:21; and

a light chain, the light chain comprising a constant region and a variable region, wherein the light chain variable region comprises SEQ ID NO:10;

(b) a linker; and